| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 83,394 | 101,472 | ||
| Marketable securities - current | 164,916 | 146,236 | ||
| Accounts receivable | 9,248 | - | ||
| Prepaid expenses | 7,747 | 13,694 | ||
| Restricted cash - current | 0 | 75 | ||
| Interest receivable | 1,589 | 1,622 | ||
| Other current assets | 5,543 | 6,871 | ||
| Total current assets | 272,437 | 269,970 | ||
| Marketable securities - long-term | 80,315 | 107,256 | ||
| Restricted cash - long-term | 721 | 721 | ||
| Operating lease right-of-use assets | 3,708 | 3,218 | ||
| Property and equipment, net | 3,083 | 3,343 | ||
| Total assets | 360,264 | 384,508 | ||
| Accounts payable | 5,871 | 4,313 | ||
| Accrued and other current liabilities | 30,093 | 25,616 | ||
| Deferred revenue - current portion | 5,763 | 8,749 | ||
| Total current liabilities | 41,727 | 38,678 | ||
| Deferred revenue - net of current portion | 8,558 | 9,632 | ||
| Other long term liabilities | 1,874 | 1,255 | ||
| Total long term liabilities | 10,432 | 10,887 | ||
| Total liabilities | 52,159 | 49,565 | ||
| Common stock, par value of 0.0001 per share 300,000,000 shares authorized, 55,120,002 and 54,032,826 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 5 | 5 | ||
| Additional paid-in capital | 747,435 | 736,276 | ||
| Accumulated other comprehensive income (loss) | 446 | 96 | ||
| Accumulated deficit | -439,781 | -401,434 | ||
| Total stockholders equity | 308,105 | 334,943 | ||
| Total liabilities and stockholders equity | 360,264 | 384,508 | ||
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)